Fig. 3: Expansion of CRISPR-edited autologous anti-CD19 or anti-BCMA CART-aIL6/IL1RA with GM-CSF/TCR KO in patients. | Cell Discovery

Fig. 3: Expansion of CRISPR-edited autologous anti-CD19 or anti-BCMA CART-aIL6/IL1RA with GM-CSF/TCR KO in patients.

From: CRISPR-edited CART with GM-CSF knockout and auto secretion of IL6 and IL1 blockers in patients with hematologic malignancy

Fig. 3

a Efficiency of GM-CSF and TCR KO in CART-aIL6/IL1RA during ex vivo expansion. b Cytotoxicity of anti-CD19 or anti-BCMA CART-aIL6/IL1RA with GM-CSF/TCR KO or WT counterpart. c–e Frequencies of CRISPR-edited CD3– CART cells in patient #1 (c), patient #2 (d), patient #3 (e), before and after infusion.

Back to article page